Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden

被引:4
作者
Svensson, Ann-Marie [1 ,2 ]
Toll, Anders [3 ]
Lebrec, Jeremie [4 ]
Miftaraj, Mervete [1 ]
Franzen, Stefan [1 ,2 ]
Eliasson, Bjoern [2 ]
机构
[1] Natl Diabet Register, Ctr Registers, Gothenburg, Sweden
[2] Univ Gothenburg, Sahlgrenska Univ Hosp, Gothenburg, Sweden
[3] Eli Lilly Sweden AB, S-16973 Solna, Sweden
[4] HaaPACS GmbH, Schriesheim, Germany
关键词
antidiabetic drug; GLP‐ 1; analogue; population study; type; 2; diabetes; GLP-1 RA TREATMENT; TREATMENT PATTERNS; MEDICATION ADHERENCE; PROPENSITY SCORE; COST; MELLITUS; OUTCOMES; AGENTS; IMPACT; CARE;
D O I
10.1111/dom.14276
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim To compare treatment persistence in patients with type 2 diabetes initiating the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) dulaglutide, exenatide once-weekly (QW), liraglutide or lixisenatide in routine clinical practice in Sweden and assess clinical outcomes. Materials and Methods We performed a retrospective study using data from several nationwide Swedish health registries, including the National Diabetes Register and other mandatory and population-based registries. Individual level data were collected from 17 361 patients who initiated GLP-1 RA treatment from 23 May 2015 to 15 October 2017, up to 2.5 years postindex (treatment start date). Treatment persistence and modification, predictors of discontinuation, HbA1c and body weight were recorded. Non-persistence was defined as a treatment gap of more than 45 days. Treatment modification included switching and augmentation. Confounding was addressed through the use of propensity scores. Results Treatment persistence was higher and treatment modifications were lower in patients initiating dulaglutide compared with those on exenatide QW, liraglutide and lixisenatide. Patients who remained on the same treatment for 1-year postindex experienced greater HbA1c reductions and a steadier decrease in body weight. Conclusions Our study suggests that in clinical practice in Sweden there is a greater persistence of treatment among patients initiating dulaglutide compared with those on exenatide QW, liraglutide and lixisenatide. Persistence with the index GLP-1 RA was closely correlated with positive clinical outcomes and thus should be considered a critical factor of patient-centric treatment in Sweden.
引用
收藏
页码:720 / 729
页数:10
相关论文
共 32 条
  • [1] Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide
    Alatorre, Carlos
    Lando, Laura Fernandez
    Yu, Maria
    Brown, Katelyn
    Montejano, Leslie
    Juneau, Paul
    Mody, Reema
    Swindle, Ralph
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (07) : 953 - 961
  • [2] Mode of administration of dulaglutide: implications for treatment adherence
    Amblee, Ambika
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 975 - 982
  • [3] Diabetes Prevalence in Sweden at Present and Projections for Year 2050
    Andersson, Tomas
    Ahlbom, Anders
    Carlsson, Sofia
    [J]. PLOS ONE, 2015, 10 (11):
  • [4] A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials
    Aroda, Vanita R.
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 : 22 - 33
  • [5] A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
    Asche, Carl
    LaFleur, Joanne
    Conner, Christopher
    [J]. CLINICAL THERAPEUTICS, 2011, 33 (01) : 74 - 109
  • [6] Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
    Austin, Peter C.
    Stuart, Elizabeth A.
    [J]. STATISTICS IN MEDICINE, 2015, 34 (28) : 3661 - 3679
  • [7] Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study
    Buysman, Erin K.
    Liu, Fang
    Hammer, Mette
    Langer, Jakob
    [J]. ADVANCES IN THERAPY, 2015, 32 (04) : 341 - 355
  • [8] Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States
    Cai, Jennifer
    Wang, Yuexi
    Baser, Onur
    Xie, Lin
    Chow, Wing
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1175 - 1186
  • [9] The Impact of Treatment Noncompliance on Mortality in People With Type 2 Diabetes
    Currie, Craig J.
    Peyrot, Mark
    Morgan, Christopher Ll
    Poole, Chris D.
    Jenkins-Jones, Sara
    Rubin, Richard R.
    Burton, Christopher M.
    Evans, Marc
    [J]. DIABETES CARE, 2012, 35 (06) : 1279 - 1284
  • [10] Davies MJ, 2018, DIABETOLOGIA, V61, P2461, DOI [10.1007/s00125-018-4729-5, 10.2337/dci18-0033]